Skip to main content
Premium Trial:

Request an Annual Quote

Dana-Farber Raises $1.2B with Focus on Personalized Cancer Treatment

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dana-Farber Cancer Institute said today that it has raised about $1.2 billion to conclude the largest capital campaign in its history — a seven-year drive whose proceeds helped establish several centers focused on developing personalized cancer care.

According to Dana-Farber, gifts raised during Mission Possible: The Dana-Farber Campaign to Conquer Cancer helped establish the Center for Cancer Genome Discovery, Blais Proteomics Center, Lurie Family Imaging Center, Linde Program in Chemical Biology, Belfer Institute for Applied Cancer Science, and the Center for Novel Experimental Therapeutics.

"The investments made in Dana-Farber during the past seven years have generated unprecedented insights into the causes and underlying mechanisms of cancer, giving us the knowledge and tools needed to provide care that is personalized to each person's cancer," Dana-Farber President Edward Benz Jr. said in a statement.

Research and care was one of four priorities for which Dana-Farber said it raised funds during the campaign. The other three include new technologies; the Jimmy Fund and unrestricted funds; and construction of the Yawkey Center for Cancer Care, a 14-story, 275,000-square-foot clinical care and research facility set for completion in January 2011.

The Yawkey Center is designed to help the cancer institute better accommodate growth in its volumes of patients and clinical trials. Between 2001 and last year, outpatient visits and infusions at Dana-Farber more than doubled from nearly 128,000 to more than 292,000, while the number of clinical trials available to Dana-Farber patients nearly doubled from 409 to 736.

To date, Dana-Farber has received more than 2 million gifts of all sizes — including 121 gifts of $1 million or more, and 820 gifts of $100,000 or more. Every member of the Board of Trustees made a gift during the campaign period, and 96 percent of senior faculty contributed very early on, the institute said.

Dana-Farber accomplished its financial mission of raising a billion dollars a year ahead of schedule in September 2009, and continued raising funds through the Sept. 30 conclusion of the effort.

"Dana-Farber has the resources to expand on its leadership role in translational, bench-to-bedside research, which will mean more cancer patients will be given a much better chance to become cancer survivors," Larry Lucchino, president and CEO of the Boston Red Sox, and co-chair of the Mission Possible campaign, said in the statement.

Filed under

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.